Dyne Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Dyne Therapeutics Inc 's ROA in the second quarter of 2026?
Dyne Therapeutics Inc recorded a cumulative net loss of $-519 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -50.33%.

However, within the Healthcare sector 566 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3890, from total ROA ranking in the first quarter of 2026 at 4600.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	36.35 %	49.77 %	78.58 %	16.97 %	-8.57 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-519	-452	-446	-424	-413
Return On Assets (TTM)	-50.33 %	-46.77 %	-50.94 %	-56.85 %	-57.83 %
DYN's Total Ranking	# 3890	# 4600	# 4086	# 4144	# 4135
Total Assets (TTM) in million	994	1,080	1,187	867	729
Seq. Total Assets Change	-7.96 %	-9.02 %	36.89 %	18.94 %	1.1 %
Seq. Net Income Change	-	-	-	-	-

DYN's 5 Years Annual ROA >> Back to DYN Management Effectiveness >> Compare DYN ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 246
Sector	# 567
Overall	# 3896

Return On Assets Statistics
High	Average	Low
108.01 %	-15.21 %	-103.66 %
(Mar 31 2021)		(Dec 31 2023)

Financial Statements
Dyne Therapeutics Inc 's Assets	$ 994 million	DYN's Balance sheet
Dyne Therapeutics Inc 's Income	$ -179 million	Quarterly DYN's Income Statement
DYN's Income by Division		See DYN's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	73.11 %	395.45 %	-50.59 %	-29.85 %	9.55 %
Total Assets in million	1,151	665	134	272	387
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-446	-317	-236	-168	-149
Annual Return On Assets	-38.78 %	-47.76 %	-175.87 %	-61.91 %	-38.57 %

DYN's 5 Years Annual ROA >> Back to DYN Management Effectiveness >> Compare DYN ROA to its Competitors

More Return On Assets Ratios
DYN's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
DYN's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for DYN's Competitors
Subscribers only: Roa for Dyne Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for DYN's Customers

You may also want to know
DYN's Roi	DYN's Inventory Turnover Ratio	DYN's Growth Rates	DYN's Dividend Comparisons
	DYN's Profitability Ratios	DYN's Asset Turnover Ratio	DYN's Dividend Growth
DYN's Roe	DYN's Valuation Ratios	DYN's Financial Strength Ratios	DYN's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-08-12T19:59:28+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.